Our advice covers:
- current status of hearing loss and tinnitus R&D - small molecule, cell-based and biologic approaches; drugs in development to treat hearing loss and tinnitus
- subtypes of acquired hearing loss: age related hearing loss, noise-induced hearing loss, ototoxicity
- subtypes of genetic hearing loss
- insight into targets and mechanistic pathways of therapeutic interest
- market size.
Action on Hearing Loss is working alongside Globe Life Sciences to produce market reports on tinnitus and age-related hearing loss to provide you with up-to-date information about these emerging therapeutic markets.
‘Hearing Disorders – Tinnitus: An Attractive But Untapped Opportunity’
The new report from Globe Life Sciences identifies tinnitus to be an attractive but under-recognised commercial opportunity for pharmacotherapies to target.
The full report provides a detailed assessment of the attractiveness of the tinnitus market as a commercial opportunity for pharmacotherapies to target, and identifies the key risks and opportunities associated with this indication. The methodology involved desk research utilising a broad range of secondary sources, combined with interviews with 10 key opinion leading clinicians (KOLs) across the US and Europe.